ICUI VS NUVA Stock Comparison
Performance
ICUI10/100
10/100
ICUI returned -45.55% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
NUVA10/100
10/100
NUVA returned -12.44% in the last 12 months. Based on SPY's performance of -8.84%, its performance is below average giving it a score of 10 of 100.
Analyst Price Targets
ICUI65/100
65/100
5 analysts offer 12-month price targets for ICUI. Together, they have an average target of 190, the most optimistic target put ICUI at 190 within 12-months and the most pessimistic has ICUI at 190.
NUVA75/100
75/100
18 analysts offer 12-month price targets for NUVA. Together, they have an average target of 58, the most optimistic target put NUVA at 64 within 12-months and the most pessimistic has NUVA at 50. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.
Technicals
ICUI25/100
25/100
ICUI receives a 25 of 100 based on 14 indicators. 3 are bullish, 10 are bearish.
NUVA89/100
89/100
NUVA receives a 89 of 100 based on 14 indicators. 12 are bullish, 1 are bearish.
Earnings
ICUI41/100
41/100
ICUI has missed earnings 3 times in the last 20 quarters.
NUVA10/100
10/100
NUVA has missed earnings 4 times in the last 20 quarters.
Profit
ICUI51/100
51/100
Out of the last 20 quarters, ICUI has had 13 profitable quarters and has increased their profits year over year on 5 of them.
NUVA67/100
67/100
Out of the last 20 quarters, NUVA has had 13 profitable quarters and has increased their profits year over year on 9 of them.
Volatility
ICUI48/100
48/100
ICUI has had a lower than average amount of volatility over the last 12 months giving it a score of 48 of 100.
NUVA46/100
46/100
NUVA has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.
All score calculations are broken down here to help you make more informed investing decisions
ICU Medical Inc Summary
Nasdaq / ICUI
Healthcare
Medical - Instruments & Supplies
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap and SwabTip disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoClave and ChemoLock closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. The company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. It also provides critical care products, such as Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
NuVasive, Inc. Summary
Nasdaq / NUVA
Healthcare
Medical Devices
NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare ICUI to other companies in the same or a similar industry.